India’s Union Health Ministry has asked states and Union territories to take action against doctors and clinical establishments offering unproven stem cell therapy outside the permitted regulatory framework.
The ministry issued its advisory on September 16, 2026. The Indian Express and The Times of India independently reported the directive on September 17, including its warning that unauthorised treatment, promotion or advertising can trigger professional and regulatory action.
Unproven stem cell therapy faces enforcement
The advisory says stem-cell therapy may be offered as routine clinical care only for conditions or indications approved by the ministry. Other uses must follow the rules governing clinical research rather than being marketed as established treatment.
The ministry specifically addressed autism spectrum disorder. It said stem-cell intervention for autism must remain within duly approved clinical trials and must not be presented as routine, standard or commercial treatment.
This distinction is important for patients and families. A therapy being studied in a clinical trial does not mean that it has been proven safe and effective for general clinical use.
Possible action against doctors and clinics
According to the reports, doctors who administer, prescribe, promote or advertise unauthorised stem-cell treatment may face proceedings for professional misconduct. The National Medical Commission had also reiterated this position in an advisory dated September 5.
Clinical establishments may face penalties or cancellation of registration where the Clinical Establishments (Registration and Regulation) Act applies. The Indian Express reported that this route is limited to the states and Union territories that have adopted the Act, while professional-ethics regulation has wider application.
Any disciplinary or licensing action would still need to follow the applicable legal process. The advisory does not mean every clinic offering a stem-cell procedure has automatically been found in violation.
Supreme Court ruling shaped the advisory
The ministry linked its direction to a Supreme Court judgment dated January 30, 2026 concerning stem-cell therapy for autism. It asked state and district authorities, as well as public and private clinical establishments, to circulate and follow the regulatory requirements.
The governing framework also includes the National Guidelines for Stem Cell Research, issued jointly in 2017 by the Indian Council of Medical Research and the Department of Biotechnology.
The Indian Express reported that the ministry’s approved list permits stem-cell therapy for specified conditions, including certain cancers and blood or autoimmune disorders. Patients should not treat that list as a self-diagnosis guide; whether a therapy is appropriate depends on the precise condition, clinical indication and qualified medical assessment.
What patients should verify
Before paying for a stem-cell intervention, patients can ask whether the proposed use is an approved standard treatment or part of a registered clinical trial. They should request the trial registration, ethics approval, treating doctor’s registration details and a written explanation of known risks and alternatives.
Marketing claims such as guaranteed recovery, treatment of many unrelated diseases or reliance mainly on testimonials deserve particular caution. Patients can seek a second opinion from an appropriate specialist and verify claims with recognised medical institutions.
The advisory is an enforcement direction, not a finding that all stem-cell research lacks value. It separates authorised care and properly supervised research from commercial claims that have not met the required evidence and approval standards.
